Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 35, Issue 10, 2008, Pages 2030-2037

  Maksymowych, Walter P ^a   Rahman, Proton ^b   Shojania, Kam ^c   Olszynski, Wojciech P ^d   Thomson, Glen T D ^e   Ballal, Shaila ^f   Wong, Robert L ^f   Inman, Robert D ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f ABBOTT LABORATORIES   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adalimumab; Ankylosing spondylitis; Metalloproteinase 3; Randomized controlled trial; Urinary type II collagen C telopeptide

Indexed keywords

ADALIMUMAB; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; STROMELYSIN; TELOPEPTIDE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLLAGEN TYPE I; COLLAGEN TYPE II; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PEPTIDES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54949093957     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
2. Dawes PT. Stoke Ankylosing Spondylitis Spine Score. J Rheumatol 1999;26:993-6.
3. Wanders AJB, Landewé RBM, Spoorenberg A, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? Arthritis Rheum 2004;50:2622-32.
4. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
5. van der Heijde DM, Landewé R, Deodar A, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab [abstract]. Ann Rheum Dis 2006;66 Suppl II:85.
6. Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology Oxford 2003;42:83-8.
7. Maksymowych WP, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-53.
8. Okada Y. Proteinases and matrix degradation. In: Harris ED Jr, Budd RC, Firestein GS, et al, editors. Kelley's textbook of rheumatology. Vol. I, Sec. I. Philadelphia: Elsevier Saunders; 2005:63-81.
9. Garnero P, Geusens P, Landewe R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S54-8.
10. Garnero P, Landewe R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56.
11. Landewe R, Geusens PMB, Boers M, et al. Markers for cartilage breakdown predict the effect of disease modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1390-9.
12. Vosse D, Landewé R, Garnero P, van der Heijde D, van der Linden S, Geusens P. Urinary CTX-II is associated with radiological damage and progression in patients with ankylosing spondylitis [abstract]. Arthritis Rheum 2007;56 Suppl:1171.
13. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporosis Int 2001;12:605-9.
14. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 2007;9:203-8.
15. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Min Res 2007;22:724-9.
16. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004;50:2942-53.
17. Yang C, Gu J, Rihi M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004;51:691-9.
18. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
19. Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005;32:1911-17.
20. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
21. Lambert RGW, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:4005-14.
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
24. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
25. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
26. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
27. Maksymowych WP, Mallon C, Richardson R, et al. Development and validation of the Edmonton Ankylosing Spondylitis Metrology Index (EDASMI). Arthritis Rheum 2006;55:575-82.
28. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
29. Maksymowych WP, Olczynski W, Sampalis J, Shojania K. The Maastricht and Spondyloarthritis Research Consortium of Canada enthesitis scores: A comparison of their reliability and responsiveness [abstract]. J Rheumatol 2006;33:382.
30. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:502-9.
31. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:703-9.
32. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007;34:1753-9.
33. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis factor (TNF)-? therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology Oxford 2002;41:484-9.
34. Garnero P, Sornay-Rendu E, Arlot M, Christiansen C, Delmas PD. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004;50:3137-44.
35. Visvanathan S, Marini JC, Braun J, et al. The effect of infliximab therapy on the modulation of inflammatory disease markers in patients with ankylosing spondylitis [abstract]. Arthritis Rheum 2004;50 Suppl:445.
36. Zwerina J, Hayer S, Tohidast-Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
37. Speden DJ, Calin AI, Ring FJ, Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002;29:516-21.
38. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
39. Matsui Y, Maeda M, Nakagami W, Iwata H. The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation. Spine 1998;23:863-8.